ClinicalTrials.gg
CompletedNCT03695367Updated Mar 2, 2026Results posted

Phase 2 Herniorrhaphy Study for Opioid Elimination

A Phase 2 interventional study of HTX-011 and Luer lock applicator in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Heron Therapeutics · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
198th of 364
63 · median 70
Started
2018
with 26 others
Phase 2
43 of 364
4 open now
Registered
153rd of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 198th largest by enrollment, is one of 27 that started in 2018, is one of 43 in phase 2, and was the 153rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a Phase 2, open-label study in subjects undergoing unilateral open inguinal herniorrhaphy.

03

Conditions studied

  • Postoperative Pain

Keywords

  • inguinal hernia
  • hernia
  • hernia surgery
  • postoperative pain
  • herniorrhaphy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.
  • Has an Physical Status of I, II, or III.
  • Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable .

Exclusion criteria

Exclusion Criteria:

  • Had any prior inguinal hernia repair except as a child (less than 6 years of age).
  • Has a planned concurrent surgical procedure (eg, bilateral herniorrhaphy).
  • Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
  • Has a or a known or suspected history of or idiosyncratic reaction to required study medications.
  • Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
  • Has taken any NSAIDs within least 10 days prior to the scheduled surgery.
  • Has taken long-acting opioids within 3 days prior to the scheduled surgery.
  • Has taken any opioids within 24 hours prior to the scheduled surgery.
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
  • Has initiated treatment with study medications within 1 month prior to study drug administration that can impact pain control.
  • Has been administered systemic within 5 half-lives or 10 days prior to administration of study drug.
  • Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
  • As per subject history and/or medical records, has active infection or is currently undergoing treatment for , , or (HIV).
  • Has uncontrolled anxiety, psychiatric, or neurological disorder.
  • Had a in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study at the discretion of the Sponsor. Subjects taking any marijuana (medical or recreational) are not allowed to participate in the study.
  • Previously participated in an HTX-011 study.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half-lives.
  • Has undergone 3 or more surgeries within 12 months.
  • Has a (BMI) >39 kg/m2.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Cohort 1: HTX-011 + MMA Regimen

    HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen.

    Drug: HTX-011 · Device: Luer lock applicator · Device: Vial access device · Drug: Ibuprofen · Drug: Acetaminophen

  • Experimental
    Cohort 2: HTX-011 + MMA Regimen + Ketorolac

    HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen and IV ketorolac.

    Drug: HTX-011 · Device: Luer lock applicator · Device: Vial access device · Drug: Ibuprofen · Drug: Acetaminophen · Drug: Ketorolac

Interventions

  • DrugHTX-011

    Drug pages: Bupivacaine · Meloxicam

    HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.

  • DeviceLuer lock applicator

    Applicator for instillation.

  • DeviceVial access device

    Device for withdrawal of drug product.

  • Ibuprofen, 600 mg.

  • Acetaminophen, 1 g.

  • Intraoperative IV ketorolac.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Receiving no Opioid Rescue

    Time frame: 72 hours

Secondary outcomes

  1. Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [IV MME])

    Time frame: 72 hours

  2. Percentge of Subjects Receiving no Opioid Rescue

    Time frame: 0-24 hours, 24-48 hours, 24-72 hours, 48-72 hours

  3. Percentge of Subjects Receiving no Opioid Rescue

    Time frame: Day 28

  4. Percentge of Subjects in Severe Pain With Numeric Rating Scale (NRS-R; Windowed Worst Observation Carried Forward) of Pain Intensity Scores >7 on a Scale of 0-10 at Any Point. NRS-R for Pain Where 0 Equals no Pain and 10 Equals Worst Pain Imaginable.

    Time frame: 72 hours

07

Results

Posted Jul 2, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + Ketorolac
Started3330
Completed3226
Not completed14
Withdrew: Missed the day 28 visit.10
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject01
Withdrew: One subject missed the day 28 visit and one subject missed the day 10 and day 28 visits.02

Outcome measures

PrimaryPercentage of Subjects Receiving no Opioid Rescue
Time frame:
72 hours
Reported as:
Count of participants · Participants
Percentage of Subjects Receiving no Opioid Rescue
ParticipantsCohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + Ketorolac
Percentage of Subjects Receiving no Opioid Rescue3027
SecondaryTotal Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [IV MME])
Time frame:
72 hours
Reported as:
Mean · MME, morphine milligram equivalents
Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [IV MME])
MME, morphine milligram equivalentsCohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + Ketorolac
Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [IV MME])0.59 ± 2.1411.32 ± 4.199
SecondaryPercentge of Subjects Receiving no Opioid Rescue
Time frame:
0-24 hours, 24-48 hours, 24-72 hours, 48-72 hours
Reported as:
Count of participants · Participants
Percentge of Subjects Receiving no Opioid Rescue
ParticipantsCohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + Ketorolac
0-24 hours3027
24-48 hours3229
24-72 hours3228
48-72 hours3328
SecondaryPercentge of Subjects Receiving no Opioid Rescue
Time frame:
Day 28
Reported as:
Count of participants · Participants
Percentge of Subjects Receiving no Opioid Rescue
ParticipantsCohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + Ketorolac
Percentge of Subjects Receiving no Opioid Rescue2824
SecondaryPercentge of Subjects in Severe Pain With Numeric Rating Scale (NRS-R; Windowed Worst Observation Carried Forward) of Pain Intensity Scores >7 on a Scale of 0-10 at Any Point. NRS-R for Pain Where 0 Equals no Pain and 10 Equals Worst Pain Imaginable.
Time frame:
72 hours
Reported as:
Count of participants · Participants
Percentge of Subjects in Severe Pain With Numeric Rating Scale (NRS-R; Windowed Worst Observation Carried Forward) of Pain Intensity Scores >7 on a Scale of 0-10 at Any Point. NRS-R for Pain Where 0 Equals no Pain and 10 Equals Worst Pain Imaginable.
ParticipantsCohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + Ketorolac
Percentge of Subjects in Severe Pain With Numeric Rating Scale (NRS-R; Windowed Worst Observation Carried Forward) of Pain Intensity Scores >7 on a Scale of 0-10 at Any Point. NRS-R for Pain Where 0 Equals no Pain and 10 Equals Worst Pain Imaginable.56

Adverse events

Collected over 28 Days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: HTX-011 + MMA Regimen0/33 (0%)0/33 (0%)5/33 (15.2%)
Cohort 2: HTX-011 + MMA Regimen + Ketorolac0/30 (0%)0/30 (0%)7/30 (23.3%)
Most frequent other events
Most frequent other events
EventCohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + Ketorolac
NauseaGastrointestinal disorders2/333/30
HypoxiaRespiratory, thoracic and mediastinal disorders3/332/30
HeadacheNervous system disorders1/332/30
DizzinessNervous system disorders0/332/30
VomitingGastrointestinal disorders0/332/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + KetorolacTotal
<=18 years000
Between 18 and 65 years302656
>=65 years347
Age, Continuous
Age, Continuous(years)Cohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + KetorolacTotal
Mean50.9 ± 13.5246.1 ± 14.9948.7 ± 14.33
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + KetorolacTotal
Female044
Male332659
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + KetorolacTotal
Hispanic or Latino14923
Not Hispanic or Latino192140
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + KetorolacTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American145
White302656
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort 1: HTX-011 + MMA RegimenCohort 2: HTX-011 + MMA Regimen + KetorolacTotal
United States333063
08

Study locations

5 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Lotus Clinical Research, LLC
    Pasadena, California 91105, United States
  • JBR Clinical Research
    Draper, Utah 84020, United States
  • JBR Clinical Research
    Murray, Utah 84107, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Nov 2018, 1 month.

Results were first posted in Jul 2021, 2 years 7 months after primary completion. A results delay was requested in Apr 2020.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2018
First posted
Oct 4, 2018
StartActual
Oct 1, 2018
Primary completionActual
Nov 20, 2018
CompletionActual
Dec 15, 2018
Results delay requested
Apr 5, 2020
Results first posted
Jul 2, 2021
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03695367
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Oct 4, 2018
Start date
Oct 1, 2018
Primary completion
Nov 20, 2018
Completion
Dec 15, 2018
Results posted
Jul 2, 2021
Last update
Mar 2, 2026

Study contacts

Neil Singla, MD
study chair · Lotus Clinical Research, LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Meloxicam

Start the discussion